Biotech: Page 18
-
Daniel Tadevosyan via Getty Images
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.
By BioPharma Dive staff • Oct. 18, 2024 -
Andrii Yalanskyi via Getty Images
Sage to cut one-third of workforce, streamline drug pipeline
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
By Delilah Alvarado • Oct. 17, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Pla2Na via Getty Images
Forbion follows string of startup exits with $2.2B fundraise
The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.
By Delilah Alvarado • Oct. 15, 2024 -
Daniel Tadevosyan via Getty Images
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.
By BioPharma Dive staff • Oct. 15, 2024 -
Daniel Tadevosyan via Getty Images
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.
By BioPharma Dive staff • Oct. 11, 2024 -
lucky-photographer via Getty Images
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.
By Gwendolyn Wu • Oct. 10, 2024 -
Jian Fan via Getty Images
Purespring raises $105M to advance gene therapy for kidney disease
The Series B round will fund a Phase 1/2 trial of the company’s experimental treatment for IgA nephropathy.
By Delilah Alvarado • Oct. 9, 2024 -
jetcityimage via Getty Images
Lilly partners with AI specialist Insitro to develop metabolic medicines
The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.
By Kristin Jensen • Oct. 9, 2024 -
Daniel Tadevosyan via Getty Images
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam is asking for approval of a drug that could rival a Pfizer blockbuster.
By BioPharma Dive staff • Oct. 9, 2024 -
Permission granted by Basecamp Research
AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines
The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.
By Gwendolyn Wu • Oct. 9, 2024 -
Permission granted by City Therapeutics
Startup led by John Maraganore raises $135M to build ‘future of RNAi’
“The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
By Ned Pagliarulo • Oct. 8, 2024 -
Permission granted by Intellia Therapeutics
Intellia starts late-stage test of CRISPR therapy for rare swelling disease
The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.
By Ned Pagliarulo • Oct. 7, 2024 -
Permission granted by Judo Bio
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
By Gwendolyn Wu • Oct. 7, 2024 -
Courtesy of Editas Medicine
Editas trades Vertex fees for upfront cash in DRI deal
The gene editing company is selling to DRI Healthcare Trust future license fees that are owed to it under an agreement with Vertex last year.
By Delilah Alvarado • Oct. 4, 2024 -
Daniel Tadevosyan via Getty Images
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
By BioPharma Dive staff • Oct. 4, 2024 -
Stock via Getty Images
An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?
An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under scrutiny.
By Meagan Parrish • Updated Oct. 7, 2024 -
ADragan via Getty Images
With $115M more, Triveni accelerates immune drug work
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.
By Gwendolyn Wu • Oct. 2, 2024 -
Retrieved from ASCO/Luke Franke 2024 on September 30, 2024
The top biopharma conferences remaining in 2025
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch the rest of 2025.
By BioPharma Dive staff • Updated June 30, 2025 -
Daniel Tadevosyan via Getty Images
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.
By BioPharma Dive staff • Oct. 1, 2024 -
Honglouwawa via Getty Images
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”
By Gwendolyn Wu • Oct. 1, 2024 -
JacobH via Getty Images
Aktis raises $175M to fuel radiopharma drug development
Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.
By Delilah Alvarado • Sept. 30, 2024 -
Daniel Tadevosyan via Getty Images
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.
By BioPharma Dive staff • Sept. 27, 2024 -
nopparit via Getty Images
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
By Jacob Bell • Updated Sept. 26, 2024 -
Pla2Na via Getty Images
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Despite a restrictive funding climate, the startup creator is “in the ‘taking lots of risk’ mode,” said co-founder and managing director Robert Nelsen.
By Gwendolyn Wu • Sept. 26, 2024 -
Michael M. Santiago via Getty Images
BioAge prices $198M IPO, validating pivot to obesity drug research
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
By Gwendolyn Wu • Sept. 25, 2024
Previous
